Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Overview: LeMaitre Vascular develops, manufactures, and markets medical devices and implants for vascular surgery, including stent grafts, contrast injectors, and endarterectomy devices. The company operates as a single segment with sales primarily in the United States, Europe, and Japan. During the period, the company executed two acquisitions (Cardiovascular Innovations, LLC and Vascular Architects) and expanded its direct sales force.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2007 |
Nine Months Ended Sep 30, 2007 |
Nine Months Ended Sep 30, 2006 |
|---|---|---|---|
| Net Sales | $10,144 | $30,342 | $25,871 |
| Gross Profit | $7,581 | $22,564 | $18,666 |
| Gross Margin | 74.7% | 74.4% | 72.2% |
| Operating Income (Loss) | $(1,541) | $(2,966) | $(246) |
| Net Income (Loss) | $(1,354) | $(1,756) | $(498) |
| Diluted EPS | $(0.09) | $(0.11) | $(0.09) |
| Cash and Cash Equivalents | $7,752 | $7,752 | $453 |
| Marketable Securities | $17,885 | $17,885 | $15,417 |
| Total Current Assets | $41,100 | $41,100 | $43,641 |
| Total Current Liabilities | $6,740 | $6,740 | $5,378 |
| Goodwill | $11,096 | $11,096 | $8,853 |
Liquidity: As of September 30, 2007, the company held $25.6 million in combined cash, cash equivalents, and marketable securities. The company has a $10 million revolving line of credit with no borrowings outstanding.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 19% for the quarter and 17% for the nine-month period compared to the prior year. Growth was driven by the Endovascular & Dialysis Access category (up 33% and 41% respectively) and international sales (up 28% and 31% respectively).
- Operating Loss: The company reported an operating loss of $1.5 million for the quarter and $3.0 million for the nine months, compared to an operating income of $0.3 million and a loss of $0.2 million in the prior year periods. This deterioration was primarily due to increased operating expenses.
- Expense Increases:
- Sales and Marketing: Increased 30% (quarter) and 33% (nine months) due to the expansion of the sales force from 36 to 58 representatives.
- General and Administrative: Increased 52% (quarter) and 37% (nine months) due to costs associated with being a public company (legal, finance, insurance).
- Research and Development: Increased 42% (quarter) and 32% (nine months) due to new product development.
- One-Time Costs: The company incurred $1.1 million in distributor termination costs during the nine months ended September 30, 2007, related to transitioning from distributors to a direct sales model in Europe. There were no such costs in the prior year.
- Acquisitions: Goodwill increased by approximately $2.2 million due to the acquisitions of Cardiovascular Innovations, LLC ($0.3 million goodwill) and Vascular Architects ($1.9 million goodwill).
Guidance, Outlook, and Risks
Management Commentary: Management expects to continue increasing operating expenses in 2007 for R&D and sales/marketing, projecting a net loss for the full year 2007. The company anticipates that increased revenues will be offset by expansion costs and distributor termination fees.
Outlook: The company believes its current cash and marketable securities are sufficient to meet working capital and capital expenditure needs for at least the next 12 months. However, additional financing may be required for future acquisitions.
Risks and Contingencies:
- Regulatory Risks: Corruption scandals within the Chinese State Food and Drug Administration (SFDA) may delay or prevent approval for the company's EndoFit Thoracic Stent Graft in China.
- Tax Audits: The company is subject to audits by the IRS (2004-2005 returns settled) and German tax authorities (2004-2006 filings). A liability of approximately $0.6 million exists for unrecognized tax benefits.
- Supplier Dependence: The company relies on single-source suppliers for critical components (e.g., nitinol stents), creating supply chain risks.
- NASDAQ Compliance: Following the resignation of a director, the company must appoint independent directors to maintain NASDAQ listing requirements by August 2008.
- Product Recalls: The company initiated a voluntary recall in 2007 regarding packaging flaws in the acquired LeverEdge Contrast Injector.
Investor Verification Checklist
- Acquisition Integration: Verify the revenue contribution and integration progress of the Cardiovascular Innovations and Vascular Architects acquisitions.
- Distributor Transition Costs: Confirm the final settlement amounts for European distributor terminations, currently estimated at $1.1 million plus $0.6 million in non-compete/consulting costs.
- Cash Burn Rate: Monitor the rate of cash consumption given the projected full-year net loss and continued investment in sales force expansion.
- Regulatory Approvals: Track the status of the clinical study and regulatory approval process for the EndoFit device in China.
- Inventory Levels: Review inventory balances ($8.1 million) relative to sales growth to assess potential obsolescence risks, particularly for acquired product lines.